{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:01:29Z","timestamp":1773298889174,"version":"3.50.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Early pregnancy loss can be treated medically with mifepristone followed by misoprostol, with ultrasonographic confirmation of pregnancy expulsion. Alternative strategies that ascertain treatment success remotely are needed. We compared percent decline in human chorionic gonadotropin (hCG) level with treatment success or failure between patients who received mifepristone pretreatment followed by misoprostol or misoprostol alone for early pregnancy loss between 5 and 12 weeks of gestation to determine a threshold decline that might predict success. Early pregnancy loss treatment success was associated with a greater percent hCG level decline compared with treatment failure, but no threshold was able to predict success. Additional research is needed to understand hCG trends after medical management of early pregnancy loss to develop reliable protocols for remote follow-up.<\/jats:p>","DOI":"10.1097\/aog.0000000000004792","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:01:23Z","timestamp":1654167683000},"page":"1149-1151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Utility and Limitations of Human Chorionic Gonadotropin Levels for Remote Follow-up After Medical Management of Early Pregnancy Loss"],"prefix":"10.1097","volume":"139","author":[{"given":"Andrea H.","family":"Roe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Abernathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne N.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arden","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanael C.","family":"Koelper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary D.","family":"Sammel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney A.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Sonalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"100716","DOI":"10.1016\/j.eclinm.2020.100716","article-title":"Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the Triple M trial): a double-blind placebo-controlled randomised trial","volume":"32","author":"Hamel","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa1715726","article-title":"Mifepristone pretreatment for the medical management of early pregnancy loss","volume":"378","author":"Schreiber","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/AOG.0000000000002899","article-title":"Early pregnancy loss. ACOG Practice Bulletin No. 200. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.contraception.2006.08.001","article-title":"Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated","volume":"75","author":"Clark","year":"2007","journal-title":"Contraception"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/AOG.0b013e3182839fda","article-title":"Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: a randomized controlled trial","volume":"121","author":"Dayananda","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.contraception.2016.12.004","article-title":"Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis","volume":"95","author":"Raymond","year":"2017","journal-title":"Contraception"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.contraception.2014.03.016","article-title":"RU OK? The acceptability and feasibility of remote technologies for follow-up after early medical abortion","volume":"90","author":"Bracken","year":"2014","journal-title":"Contraception"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/01.AOG.0000142712.80407.fd","article-title":"Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve","volume":"104","author":"Barnhart","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.fertnstert.2003.08.041","article-title":"Hormone pattern after misoprostol administration for a nonviable first-trimester gestation","volume":"81","author":"Barnhart","year":"2004","journal-title":"Fertil Steril"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/ajo.12607","article-title":"Utility of betahCG monitoring in the follow-up of medical management of miscarriage","volume":"57","author":"Petersen","year":"2017","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.contraception.2016.09.007","article-title":"Serum human chorionic gonadotropin (hCG) trend within the first few days after medical abortion: a prospective study","volume":"95","author":"Pocius","year":"2017","journal-title":"Contraception"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"551.e1","DOI":"10.1016\/j.ajog.2020.04.006","article-title":"Management of early pregnancy loss with mifepristone and misoprostol: clinical predictors of success from a randomized trial","volume":"223","author":"Sonalkar","year":"2020","journal-title":"Am J Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:01:45Z","timestamp":1745434905000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004792","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"2021-12-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}